An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-Serodiscordant couples for targeted HIV-1 prevention

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 3, 2013, Pages 339-347

  Kahle, Erin M ^a   Hughes, James P ^a   Lingappa, Jairam R ^a,b   John Stewart, Grace ^a,b   Celum, Connie ^a   Nakku Joloba, Edith ^c   Njuguna, Stella ^d   Mugo, Nelly ^a,e   Bukusi, Elizabeth ^d   Manongi, Rachel ^f   Baeten, Jared M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c MAKERERE UNIVERSITY   (Uganda)

^d Research Care Training Program   (Kenya)

^e KENYATTA NATIONAL HOSPITAL   (Kenya)

^f KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

Author keywords

Clinical prediction rule; HIV 1 acquisition; HIV 1 serodiscordant couples

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE; PLACEBO; TENOFOVIR DISOPROXIL;

ADULT; AFRICA; ARTICLE; BLOOD SAMPLING; CLINICAL RESEARCH; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE TRANSMISSION; DOUBLE BLIND PROCEDURE; EXTERNAL VALIDITY; FEMALE; HETEROSEXUALITY; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; INFECTION PREVENTION; INTERNAL VALIDITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEROLOGY; VIRUS LOAD;

EID: 85028104088     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31827e622d     Document Type: Article

References (47)

1. UNAIDS. AIDS Epidemic Update. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization. 2009; 304.
2. Dunkle KL, Stephenson R, Karita E, et al. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet. 2008;371: 2183-2191.
3. Chemaitelly H, Cremin I, Shelton J, et al. Distinct HIV discordancy patterns by epidemic size in stable sexual partnerships in sub-Saharan Africa. Sex Transm Infect. 2012;88:51-57.
4. Liechty CA. The evolving role of HIV counseling and testing in resource-limited settings: HIV prevention and linkage to expanding HIV care access. Curr Infect Dis Rep. 2005;7:154-158.
5. Grabbe KL, Bunnell R. Reframing HIV prevention in sub-Saharan Africa using couple-centered approaches. JAMA. 2010;304:346-347.
6. Allen S, Meinzen-Derr J, Kautzman M, et al. Sexual behavior of HIV discordant couples after HIV counseling and testing. AIDS. 2003;17:733-740.
7. Farquhar C, Kiarie JN, Richardson BA, et al. Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission. J Acquir Immune Defic Syndr. 2004;37:1620-1626.
8. Brubaker SG, Bukusi EA, Odoyo J, et al. Pregnancy and HIV transmission among HIV-discordant couples in a clinical trial in Kisumu, Kenya. HIV Med 2011;12:316-321.
9. Kaiser R, Bunnell R, Hightower A, et al. Factors associated with HIV infection in married or cohabitating couples in Kenya: results from a nationally representative study. PLoS One. 2011;6:e17842.
10. Venkatesh KK, de Bruyn G, Lurie MN, et al. Sexual risk behaviors among HIV-infected South African men and women with their partners in a primary care program: implications for couples-based prevention. AIDS Behav. 2012;16:139-150.
11. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357:1149-1153.
12. Lingappa JR, Hughes JP, Wang RS, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One. 2010;5:e12598.
13. Mermin J, Musinguzi J, Opio A, et al. Risk factors for recent HIV infection in Uganda. JAMA. 2008;300:540-549.
14. Fox J, White PJ, Weber J, et al. Quantifying sexual exposure to HIV within an HIV-serodiscordant relationship: development of an algorithm. AIDS. 2011;25:1065-1082.
15. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092-2098.
16. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
17. Baeten J, Celum C. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. Paper presented at: 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 17-20, 2011; Rome, Italy.
18. WHO. Guidance on Couples HIV Testing and Counseling and Antiretroviral Therapy for Treatment and Prevention in Serodiscordant Couples: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2011.
19. Wasson JH, Sox HC, Neff RK, et al. Clinical prediction rules. Applications and methodological standards. N Engl J Med 1985;313:793-799.
20. Laupacis A, Sekar N, Stiell IG. Clinical prediction rules. A review and suggested modifications of methodological standards. JAMA. 1997;277: 488-494.
21. Beattie P, Nelson R. Clinical prediction rules: what are they and what do they tell us? Aust J Physiother. 2006;52:157-163.
22. Shapiro SE. Guidelines for developing and testing clinical decision rules. West J Nurs Res. 2006;28:244-253.
23. McGinn TG, Guyatt GH, Wyer, et al. Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence- Based Medicine Working Group. JAMA. 2000;284:79-84.
24. Menza TW, Hughes JP, Celum CL, et al. Prediction of HIV acquisition among men who have sex with men. Sex Transm Dis. 2009;36: 547-555.
25. Lingappa JR, Kahle E, Mugo N, et al. Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One. 2009;4:e5272.
26. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010;362:427-439.
27. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;12:19-26.
28. Mujugira A, Baeten JM, Donnell D, et al. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral preexposure prophylaxis for HIV-1 prevention. PLoS One. 2011;6:e25828.
29. Campbell MS, Mullins JI, Hughes JP, et al. Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One. 2011:6:e16986.
30. Kiernan M, Kraemer HC, Winkleby MA, et al. Do logistic regression and signal detection identify different subgroups at risk? Implications for the design of tailored interventions. Psychol Methods. 2001;6:35-48.
31. Hira SK, Ngandu N, Wadhawan D, et al. Clinical and epidemiological features of HIV infection at a referral clinic in Zambia. J Acquir Immune Defic Syndr. 1990;3:87-91.
32. Beyrer C. HIV epidemiology update and transmission factors: risks and risk contexts-16th International AIDS Conference epidemiology plenary. Clin Infect Dis. 2007;44:981-987.
33. Quinn TC, Overbaugh J. HIV/AIDS in women: an expanding epidemic. Science. 2005;308:1582-1583.
34. McClellan MK, Patel R, Kadzirange G, et al. Fertility desires and condom use among HIV-positive women at an antiretroviral roll-out program in Zimbabwe. Afr J Reprod Health. 2010;14:27-35.
35. Heffron R, Were E, Celum C, et al. A prospective study of contraceptive use among African women in HIV-1 serodiscordant partnerships. Sex Transm Dis. 2010;37:621-628.
36. Gray RH, Li X, Kigozi G, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369:657-666.
37. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643-656.
38. Hallet TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modeling study. PLoS Med 2011;8:e1001123.
39. WHO. Guidance on Couples HIV Testing and Counseling Including Antiretroviral Therapy for Treatment and Prevention in Serodiscordant Couples: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2012.
40. Global HIV Prevention Working Group, ed. New Approaches to HIV Prevention: Accelerating Research and Ensuring Future Access. Washington, DC: Bill & Melinda Gates Foundation and Henry J. Kaiser Family Foundation; 2006.
41. Lagakos SW GA, ed. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press; 2008.
42. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One. 2008;3:e1474.
43. Padian NS, McCoy SI, Balkus JE, et al. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS. 2010;24: 621-635.
44. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342:921-929.
45. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes. 2004;11:24-35.
46. Corey L, Wald A, Celum CL, et al. The effects of herpes simplex virus-1 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr. 2004;35:435-445.
47. CDC. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. Centers for Disease Control and Prevention. MMWR 2011;60:65-68.